BRIEF-Relypsa says Phase 4 TOURMALINE study meets primary endpoint

* Announces phase 4 study shows veltassa demonstrated similar efficacy and safety whether given with or without food in patients with hyperkalemia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.